| 25.94 0.47 (1.85%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.57 | 1-year : | 32.84 |
| Resists | First : | 27.02 | Second : | 28.12 |
| Pivot price | 26.04  |
|||
| Supports | First : | 25.26 | Second : | 21.01 |
| MAs | MA(5) : | 25.71 |
MA(20) : | 26.36 |
| MA(100) : | 26.67 |
MA(250) : | 0 | |
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 24.2 |
D(3) : | 23.6 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 29.15 | Low : | 2.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CANC ] has closed above bottom band by 45.9%. Bollinger Bands are 27.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.98 - 26.12 | 26.12 - 26.26 |
| Low: | 25.45 - 25.64 | 25.64 - 25.82 |
| Close: | 25.66 - 25.94 | 25.94 - 26.2 |
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Fri, 19 Apr 2024
9 Best Biotech ETFs for 2024 - AOL
Fri, 19 Apr 2024
MSN - MSN
Thu, 18 Apr 2024
The Life Sciences Present A Golden Opportunity For Investors. Learn How! - MSN
Mon, 08 Apr 2024
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond - Yahoo Finance UK
Mon, 22 Jan 2024
GILD Stock Tumbles 10% And Sacrifices A Breakout On Its Surprise Lung Cancer Treatment Flop - Investor's Business Daily
Tue, 21 Nov 2023
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|